HighTower Advisors
ZSAN

HighTower Advisors’s Zosano Pharma Corporation ZSAN Stock Holding History

HighTower Advisors’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-329
Closed -$58K – 2401
2018
Q1 		$58K Buy
+329
New +$110K ﹤0.01% 2011

Other funds holding ZSAN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

HighTower Advisors's ZSAN Position: Q2 2018 in Review

HighTower Advisors sold out of Zosano Pharma Corporation (ZSAN) in Q2 2018, closing a stake of 329 shares — an estimated $58K sold.

HighTower Advisors first reported a position in ZSAN in Q1 2018 and held it in 1 quarter. The position peaked at $58K in Q1 2018. 25 funds tracked by Wall St. Rank hold ZSAN as of Q2 2018.

  • HighTower Advisors reported no remaining Zosano Pharma Corporation position as of Q2 2018 after selling out during the quarter.
  • HighTower Advisors sold 329 Zosano Pharma Corporation shares in Q2 2018, an estimated $58K.
  • HighTower Advisors first reported a position in Zosano Pharma Corporation in Q1 2018 and held it in 1 quarter.
  • HighTower Advisors's Zosano Pharma Corporation position peaked at $58K in Q1 2018.
  • 25 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q2 2018.

Based on HighTower Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.